Parkin antibody, Parkin Antibody, Rabbit Polyclonal Antibody

Alphabetical Listing of Primary Antibodies:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Alphabetical Listing of Proteins:	f\| 0-4 \| 5-9 \| A \| B \| C \| D \| E \| F \| G \| H \| I \| J \| K \| L \| M \| N \| O \| P \| Q \| R \| S \| T \| U \| V \| W \| X \| Y \| Z \|
Peptides \| Secondary Antibodies \| ELISA Kits

Parkin Antibody, Rabbit Polyclonal Antibody

Catalog Number: 18-272-196411

Buy Parkin antibody -

Volume:

Related Product Names:

- Parkin antibody; Parkin; FRA6E PARK 2 PARK2 PRKN; Parkin
- Rabbit polyclonal to Parkin; FRA6E PARK 2 PARK2 PRKN; E3 ubiquitin-protein ligase parkin

- Gene Information - Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.

Gene Name: Parkin	Gene Name Synonym: FRA6E PARK 2 PARK2 PRKN
Gi #: N/A	NCBI Acc #: NP_004553.2	Swiss Prot Acc #: O60260
Length (aa): N/A	Mol. Weight (Da): 51641	Chrom Location: N/A

Isotype: IgG

Immunogen: Synthetic peptide (unfortunately, the amino acid sequence is considered to be commercially sensitive) (Human) (N terminal).

Antigen Species: Human

Positive Control: Brain

Target: Parkin

Concentration: 2 mg/ml

Storage Buffer: Phosphate-buffered saline, pH 7.4 containing 1% BSA and 0.09% sodium azide

Application Note: IHC-P: Use at a dilution of 1/30 for 10 minutes at RT. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0 for 10 minutes followed by cooling at RT for 20 minutes. 18-272-196411 demonstrates cytoplasmic staining. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user.

Source/Host: Rabbit

Purity/Purification: Immunogen affinity purified

Clonality: Polyclonal

Crossreactivity: Cross-reacts with Human, Mouse and Rat. Not yet tested in other species.

Format: Liquid

Storage: Keep as concentrated solution, aliquot and store at 4C. Do not freeze.

Shipping: Products may be shipped on ice pack or dry ice.

APPLICATIONS for PARKIN ANTIBODY:

IHC-P: Tested

TESTING: (secondary reagents and protocols )

Not Available

PARKIN ANTIBODY TARGET DESCRIPTION:

Synonym Names for Parkin antibody: Parkin; FRA6E PARK 2 PARK2 PRKN; Rabbit polyclonal to Parkin; FRA6E PARK 2 PARK2 PRKN; E3 ubiquitin-protein ligase parkin

Parkinson's Disease, the second most common neurodegenerative disease after Alzheimer's Disease, is characterized by the loss of dopaminergic neurons and the presence of Lewy bodies (comprised of alpha-synuclein and parkin inclusions). Autosomal Recessive Juvenile Parkinsonism (AR-JP) is a recently described form of Parkinson's Disease that has been linked to a gene that codes for parkin. Parkin, a 52 kDa protein, has a suggested role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING-type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome.

Function: Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP and SEPT5. May play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin E during neuronal apoptosis. May represent a tumor suppressor gene.

Pathway: Protein modification; protein ubiquitination.

Subunit: Forms an E3 ubiquitin ligase complex with UBE2L3 or UBE2L6. Part of a SCF-like complex, consisting of PARK2, CUL1 and FBXW7. Interacts with SNCAIP. Binds to the C2A and C2B domains of SYT11. Interacts and regulates the turnover of SEPT5. Part of a complex, including STUB1, HSP70 and GPR37. The amount of STUB1 in the complex increases during ER stress. STUB1 promotes the dissociation of HSP70 from PARK2 and GPR37, thus facilitating PARK2-mediated GPR37 ubiquitination. HSP70 transiently associates with unfolded GPR37 and inhibits the E3 activity of PARK2 whereas, STUB1 enhances the E3 activity of PARK2 through promotion of dissociation of HSP70 from PARK2-GPR37 complexes. Interacts with PSMD4 and PACRG. Interacts with LRRK2. Interacts with RANBP2. Interacts with SUMO1 but not SUMO2, which promotes nuclear localization and autoubiquitination.

Subcellular Location: Cytoplasm. Nucleus. Note=Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies.

Tissue Specificity: Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis.

Domain: The ubiquitin-like domain binds the PSMD4 subunit of 26S proteasomes.

Ptm: Auto-ubiquitinates in an E2-dependent manner leading to its own degradation.

Ptm: S-nitrosylated. The inhibition of PARK2 ubiquitin E3 ligase activity by S-nitrosylation could contribute to the degenerative process in PD by impairing the ubiquitination of PARK2 substrates.

Disease: Defects in PARK2 are a cause of Parkinson disease (PD) [MIM:168600]. PD is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology of PD involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.

Disease: Defects in PARK2 are the cause of autosomal recessive early onset Parkinson disease 2 (PARK2) [MIM:600116]; also known as early-onset parkinsonism with diurnal fluctuation (EPDF) or autosomal recessive juvenile Parkinson disease (PDJ). PARK2 is symptomatically different in several aspects from idiopathic Parkinson disease, although classic symptoms such as bradykinesia, rigidity and tremor are present. Additional clinical features include early DOPA-induced dyskinesia, diurnal fluctuation of the symptoms, sleep benefit, dystonia and hyper-reflexia. PARK2 is usually characterized by onset before 40, with a mean age at onset of 23.2 years. Pathologically, PARK2 patients show loss of dopaminergic neurons in the substantia nigra, similar to that seen in Parkinson disease; however, Lewy bodies (intraneuronal accumulations of aggregated proteins) are absent.

Disease: Defects in PARK2 may be involved in the development and/or progression of ovarian cancer.

Miscellaneous: The parkin locus (PRKN), adjacent to the 6q telomere is hyper-recombinable and lies within FRA6E, the third most common fragile site in tumor tissue.

Similarity: Belongs to the RBR family. Parkin subfamily.

Similarity: Contains 1 IBR-type zinc finger.

Similarity: Contains 2 RING-type zinc fingers.

Similarity: Contains 1 ubiquitin-like domain.

Parkin reacts with cross-reacts with human, mouse and rat. not yet tested in other species..

OMIM: 168600; phenotype. [NCBI / EBI]
600116; phenotype. [NCBI / EBI]
602544; gene. [NCBI / EBI]

Pathways:
KEGG pathway: Neurodegenerative Disorders 01510
KEGG pathway: Parkinson's disease 05020

Products similar to Parkin antibody:

IgG

PGP9.5 [10A1] *B1G1, IgG

Parkin (ready-to-use), IgG

PGP9.5, IgG

Parkin, IgG

PGP9.5 (ready-to-use), IgG

PRODUCT INTERACTIONS:

SUGGESTED ANITBODY REAGENTS - GenWay has an extensive selection of reagents useful for antibody applications. Find blocking buffers, stop reagents, chemiluminescent substrates, diluents, Immunohistochemistry reagents & more.

Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.

Precautions: Parkin antibody is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.

Important Notes: During shipment, small volumes of Parkin antibody vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.

Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about Parkin antibody, all related information, articles, resources about Parkin antibody are being stored on our online database. Let us know if you have questions regarding this product.

Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed.

GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.

Thank you for visiting GenWay Biotech's Datasheet. GenWay is the world's leader in chicken, IgY antibody production, producing over 900 quality polyclonal IgY antibodies to date. From our unique recombinant protein production, utilizing a variety of protein expression systems, GenWay's polyclonal IgY antibodies incorporate more epitopes, increasing the success rate for ELISA, western blot, immunohistochemistry (IHC), immunocytochemistry (ICC), and many more immunoassays.



GenWay Biotech, Inc. 6777 Nancy Ridge Drive, San Diego, CA 92121 Tel: (858)458-0866 Fax: (858)458-0833 Email: sales@genwaybio.com www.genwaybio.com ©1998 - 2010 GenWay Biotech, Inc. - All Rights Reserved